Research Topics
Species | M J EdelmanSummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lungMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
J Thorac Oncol 7:1618-21. 2012..The objective of this study was to determine the activity of EC145 in patients with chemotherapy refractory lung adenocarcinoma, whose tumors expressed the FR as determined by EC20 imaging...
Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's viewMartin J Edelman
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
J Thorac Oncol 7:1331-6. 2012..We raise several issues regarding the design and execution of these studies, which question the validity of these conclusions, and explore aspects of the trial results concerning the optimal use of this approach, if it is to be accepted...- Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistanceMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Clin Lung Cancer 13:171-80. 2012..Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development... - CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304Martin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Thorac Oncol 7:649-54. 2012.... - An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancerMartin J Edelman
Department of Medical Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Semin Oncol 32:S3-8. 2005..Numerous questions have arisen regarding how to best incorporate EGFR-targeted agents into patient management, as well as the role of the clinical laboratory in these decisions and the design of future trials... - The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, 21201, USA
Clin Lung Cancer 7:S64-6. 2005..This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC... - Second-line chemotherapy and beyond for non-small-cell lung cancerMartin J Edelman
Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21126, USA
Clin Adv Hematol Oncol 2:373-8. 2004..Numerous other agents with diverse mechanisms are currently undergoing evaluation in this setting. This review evaluates the population eligible for such treatments and discusses recent trials in second and subsequent lines of therapy... - Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancerMartin J Edelman
University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201 1595, USA
J Clin Oncol 23:5774-8. 2005..Unfortunately, a plateau in efficacy with currently available agents has been reached. Previous studies of the retinoid, bexarotene, a retinoid X receptor-specific ligand, have indicated that it may improve outcome in advanced NSCLC... - Lung cancer - Second Annual Winter ConferenceMartin J Edelman
University of Maryland, Division of Hematology/Oncology, Greenebaum Cancer Center, Baltimore, 21201, USA
IDrugs 8:366-9. 2005 - Evidence-based approaches to overcoming barriers to clinical trial accrualMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Cancer J 10:288-9. 2004 - Novel cytotoxic agents for non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Thorac Oncol 1:752-5. 2006..It has also demonstrated some single-agent cytotoxic activity... - Geographic variation in the second-line treatment of non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21136, USA
Semin Oncol 33:S39-44. 2006..These geographic and ethnic differences in toxicity and efficacy will need to be considered in the design and comparison of future clinical trials... - Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumorsMartin J Edelman
Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
Clin Cancer Res 13:2667-74. 2007..Carboplatin was escalated from an area under the curve (AUC) of 3 to an AUC of 5. UCN-01 was escalated from 50 to 90 mg/m(2)... - Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203Martin J Edelman
University of Maryland Greenebaum Cancer Center, Division of Hematology Oncology 111H, 22 South Greene Street, Baltimore, MD 21201 1595, USA
J Clin Oncol 26:848-55. 2008.... - Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancerMartin J Edelman
Division of Medical Oncology, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
Ann Thorac Surg 86:903-10. 2008..This study was designed to determine the ability to intensify our prior approach utilizing hyperfractionated radiation and more aggressive consolidative chemotherapy... - Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancerMartin J Edelman
University of Maryland, Greenebaum Cancer Center, Baltimore, MD 21201, USA
Clin Lung Cancer 10:S30-4. 2009..New antimicrotubulin agents, including the epothilones, colchicine-binding antivascular agents, and vinca alkaloids, are also discussed... - Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, United States of America
Lung Cancer 68:84-8. 2010.... - Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analogMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
J Thorac Oncol 4:1550-4. 2009..1 MeV beta radiotherapy. To evaluate the safety of this approach, a phase I dose-escalation study of Re-188 P2045 in SSTR-positive lung cancer was performed... - Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Thorac Oncol 6:786-9. 2011..MGd selectively targets tumor cells, disrupting energy metabolism and repair mechanisms, rendering cells more prone to apoptosis. Preclinical studies with MGd and pemetrexed show significant tumor growth delay in lung cancer cell lines... - Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304Martin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
J Thorac Oncol 6:1902-6. 2011.... - Treatment options for brain metastases in patients with non-small-cell lung cancerSadaf Taimur
Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Curr Oncol Rep 5:342-6. 2003..The treatment timing of chemotherapy and radiotherapy should be individualized... - Clinical and pharmacologic study of tributyrin: an oral butyrate prodrugMartin J Edelman
Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, USA
Cancer Chemother Pharmacol 51:439-44. 2003..Given in vitro data that differentiating activity requires continuous butyrate exposure, the short t1/2 of the drug and a desire to mimic the effects of an intravenous infusion, we evaluated a three times daily schedule... - Neoadjuvant chemotherapy in early-stage non-small cell lung cancerM J Edelman
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, USA
Expert Rev Anticancer Ther 1:229-35. 2001..Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments... - Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
J Thorac Oncol 5:110-6. 2010..Because the potential benefits of systemic therapy in patients with BM are uncertain, we analyzed data from a recent phase III study... - The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancerMartin J Edelman
Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Curr Treat Options Oncol 4:45-53. 2003..Therefore, mediastinal sampling must be repeated after chemoradiotherapy and before surgery... - Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resectionMartin J Edelman
Division of Hematology and Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Curr Treat Options Oncol 3:67-73. 2002..New methods of surveillance, postoperative risk stratification, and emerging therapies may alter these recommendations for postoperative surveillance of patients with early stage NSCLC in the future... - Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell linesM J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore 21201 1595, USA
Cancer Chemother Pharmacol 48:141-4. 2001..To evaluate in vitro interactions of carboplatin, gemcitabine and paclitaxel in molecularly defined non-small-cell lung cancer lines... - Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxelM J Edelman
Cancer Center, University of California Davis, Davis, California, USA
Cancer 92:146-52. 2001.... - Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancerMartin J Edelman
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Lung Cancer 38:S37-43. 2002..Trials are under way or planned for the addition of novel agents such as C225, UCN-01, PKC-alpha antisense, bexarotene, COX-2 inhibitors and other agents... - Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxelMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
Clin Cancer Res 10:5022-6. 2004..CONCLUSIONS: Sequential therapy, as used in this study, resulted in comparable efficacy to previous Southwest Oncology Group trials of two drug combinations in this population; however, it failed to meet criteria for further study... - New approaches to treatment of metastatic bladder cancerM J Edelman
Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201 1595, USA
Curr Oncol Rep 2:379-85. 2000..Recently, a number of new chemotherapeutic agents have become available. This report summarizes the current experience with these agents and combinations... - Promising new agents in the treatment of non-small cell lung cancerM J Edelman
Division of Hematology and Oncology, University of California, Davis, USA
Cancer Chemother Pharmacol 37:385-93. 1996..The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed... - Optimal duration of chemotherapy in advanced non-small cell lung cancerMaryam B Lustberg
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
Curr Treat Options Oncol 8:38-46. 2007.... - Advanced non-small cell lung cancerM J Edelman
University of Maryland Greenebaum Cancer Center, 22 S. Greene Street, Baltimore, MD 21201-1595, USA
Curr Treat Options Oncol 2:51-62. 2001..A plethora of new agents targeting angiogenesis, tumor invasiveness, the hypoxic environment of tumors, and the cell cycle are currently in development... - Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium TrialP N Lara
Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
Cancer Chemother Pharmacol 48:22-8. 2001..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status... - Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancerMartin J Edelman
Division of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201-1595, USA
Lung Cancer 39:197-9. 2003..In 40% of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m(2) was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered... - Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancerAmy J Davidoff
Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland Baltimore, 220 Arch St, 12th Floor, Room 214, Baltimore, MD 21201, USA
J Clin Oncol 28:2191-7. 2010..This study extends recent population-based analyses focusing on treatment and survival benefit from use of platinum-doublet therapy, and addressing the role of performance status (PS)... - New directions in the treatment of non-small cell lung cancer: an overviewM J Edelman
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
Oncologist 6:1-3. 2001..Clearly, vinorelbine is an active agent which is well tolerated and suitable for use in the management of NSCLC. It is likely to play a greater role in the future... - Recent developments in the chemotherapy of advanced esophageal cancerM J Edelman
Division of Hematology Oncology, Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA
Chest Surg Clin N Am 10:561-7. 2000..Numerous agents with potential activity in esophageal carcinoma based on their putative mechanisms of action are in development. Only clinical trials can establish the role of these agents in the clinic... - Phase I study of docetaxel and topotecan in patients with solid tumorsK H Tkaczuk
University of Maryland Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201, USA
Cancer Chemother Pharmacol 46:442-8. 2000.... - Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancerBenjamin B Bridges
University of Maryland Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Lung Cancer 61:61-6. 2008..We evaluated the efficacy of sequential, dose attenuated carboplatin/gemcitabine followed by paclitaxel in patients with PS=2,3, HIV infection or after solid organ transplantation... - Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgeryAshish B Patel
Department of Radiation Oncology, University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
Int J Radiat Oncol Biol Phys 60:1106-12. 2004.... - Pemetrexed-induced typhlitis in non-small cell lung cancerMarianna Shvartsbeyn
Department of Internal Medicine, University of Maryland, Baltimore, Maryland, USA
J Thorac Oncol 3:1188-90. 2008..Nevertheless, it is increasingly recognized as a complication of therapy in solid tumors. We present the first documented case of typhilitis after treatment with pemetrexed and successful therapy with supportive treatment... - Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgeryTodd W Flannery
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Int J Radiat Oncol Biol Phys 72:19-23. 2008..To report the outcome of patients with synchronous, solitary brain metastasis from non-small-cell lung cancer (NSCLC) treated with gamma knife stereotactic radiosurgery (GKSRS)... - Gemcitabine in combination with new platinum compounds: an updateD R Gandara
Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
Oncology (Williston Park) 15:13-7. 2001..Here we review recent studies investigating gemcitabine plus carboplatin and preliminary data regarding combinations of gemcitabine with the new platinum analog oxaliplatin... - Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospectsMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, MD, USA
Expert Opin Pharmacother 4:843-52. 2003..Current research is focusing on the role of newer drugs including novel antitubulin agents, growth factor receptor antagonists, eicosanoid modulators and various other agents... - Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapyRoger Hakimian
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
J Thorac Oncol 2:268-72. 2007..There is a very limited literature regarding the treatment and outcome of patients with both diseases, particularly since the advent of highly active antiretroviral therapy (HAART) for HIV infection... - Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiationMark J Krasna
St Joseph Cancer Institute, Towson, University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland 21204, USA
Ann Thorac Surg 89:200-6; discussion 206. 2010..We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer... - Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaPhilip C Mack
Cancer and Molecular Research Laboratory, Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
Cancer Chemother Pharmacol 51:337-48. 2003..These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity... - Phase I trial of gemcitabine and paclitaxel in advanced solid tumorsNelson Lim
Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA
Cancer Invest 21:7-13. 2003..The recommended phase II dose is gemcitabine 1000 mg/m2 and paclitaxel 150 mg/m2 on days one and eight every 21 days. The antitumor activity observed with this regimen warrants further investigation... - Management of common symptoms of advanced lung cancerMichelle Bedor
University of Maryland Greenebaum Cancer Center, 22 S Greene Street, Baltimore, MD 21201, USA
Curr Treat Options Oncol 6:61-8. 2005..Understanding of coping strategies may aid the medical provider in assisting the patient during his or her illness... - The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell linesElizabeth K Balcer-Kubiczek
Department of Radiation Oncology, Radiation Oncology Research Laboratory, Universtity of Maryland School of Medicine, 655 W Baltimore Street, BRB 6 009, Baltimore, MD 21201, USA
Cancer Chemother Pharmacol 59:781-7. 2007.... - Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara
Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
Cancer 100:82-8. 2004..However, the toxicities of platinum-based chemotherapy are considerable. Regimens with reduced toxicity that are applicable to a broader group of TCC patients without sacrificing activity therefore are of interest... - Promoter methylation and response to chemotherapy and radiation in esophageal cancerJames P Hamilton
Division of Gastroenterology, University of Maryland School of Medicine, Baltimore, Maryland, USA
Clin Gastroenterol Hepatol 4:701-8. 2006..In addition, increased methylation of a 9-gene panel correlated significantly with poor responsiveness to chemoradiation... 
The utility of follow-up testing after curative cancer therapy. A critical review and economic analysisM J Edelman
Division of Hematology and Oncology, Veterans Affairs Northern California Health Care System, Martinez 94553, USA
J Gen Intern Med 12:318-31. 1997..Though data are limited, this more restrictive policy of follow-up testing does not appear to adversely impact patient quality of life and result in dramatic cost of savings to the health care system...- A novel, broad-spectrum anticancer compound containing the imidazo[4,5-e][1,3]diazepine ring systemMin Xie
Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, Maryland 21250, USA
Bioorg Med Chem Lett 20:4386-9. 2010..The long alkyl chain attached to the six-position of the heterocyclic ring of 1 appears to be necessary for the observed biological activity... - Successful treatment of small cell lung cancer during pregnancyPaul G Kluetz
University of Maryland, Department of Internal Medicine, MD 21201, United States
Lung Cancer 61:129-30. 2008..We report a case of a pregnant female with limited stage small cell lung carcinoma treated at 27 weeks gestation with cisplatin and etoposide and subsequent delivery of a healthy child... - Treatment options for brain metastases in patients with non-small cell lung cancerSadaf Taimur
Division of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Curr Treat Options Oncol 4:89-95. 2003..The treatment timing of chemotherapy and radiotherapy should be individualized... - High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survivalKing F Kwong
Division of Thoracic Surgery, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD, USA
J Thorac Cardiovasc Surg 129:1250-7. 2005..Similar to other studies, late central nervous system relapse is problematic and indicates a need for assessing the role of prophylactic cranial irradiation in this disease... - MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cellsMinu K Srivastava
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250, USA
Int J Cancer 127:2612-21. 2010.... - Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignanciesEdith A Perez
Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Cancer Invest 21:1-6. 2003..Tamoxifen has been reported to enhance the antitumor activity of cisplatin in preclinical models by modulation of protein kinase C signal transduction and apoptosis-related pathways... - KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cellsPornima Phatak
Department of Pharmacology, Cytogenetics Laboratory, University of Maryland, Baltimore, MD, USA
Clin Cancer Res 14:4593-602. 2008..In this study, we elucidated the mode of action of KML001 and investigated its effects on telomerase and telomeres... - Cancer stem cells and individualized therapySaranya Chumsri
Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
Cancer Genomics Proteomics 4:165-74. 2007..Here, we provide a current overview of cancer stem cell biology and highlight possibilities for targeted intervention with existing and novel experimental anticancer agents... - Management of paraneoplastic syndromes in lung cancerLeno Thomas
Division of Hematology-Oncology, Greenebaum Cancer Center, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21201, USA
Curr Treat Options Oncol 5:51-62. 2004..Specific recommendations for the management of the most common paraneoplastic syndromes, including cachexia, hypercalcemia, and hyponatremia, are provided... - Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemiasKen Shiozawa
Program in Experimental Therapeutics, University of Maryland Marlene and Stewart Greenebaum Cancer Center, and Division of Hematology and Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Clin Cancer Res 15:1698-707. 2009..In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias... - West Nile virus presenting as opsoclonus-myoclonus cerebellar ataxiaJaswinder S Khosla
Department of Neurology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA
Neurology 64:1095. 2005 - Lung cancer in women: emerging differences in epidemiology, biology, and therapyLeno Thomas
University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA
Chest 128:370-81. 2005..These differences in both biology and outcome will be important considerations in the design of future trials of screening and therapy for lung cancer... - Bronchogenic carcinoma in solid organ transplant recipientsYanis Bellil
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
Curr Treat Options Oncol 7:77-81. 2006..Treatment is similar to that of patients who are nontransplanted with similar stage, histology, and performance status... - Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cellsMinu K Srivastava
Department of Biological Sciences, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA
Cancer Immunol Immunother 57:1493-504. 2008..The absence of invariant chain promotes the presentation of endogenously synthesized tumor antigens, and the activation of MHC II-restricted, tumor-antigen-specific CD4(+) T cells... - Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancerFrank C Detterbeck
Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut 06520 8062, USA
J Thorac Oncol 3:37-45. 2008..Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer. Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state... - Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713Martin J Edelman
Southwest Oncology Group (S9713, Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, USA
J Clin Oncol 22:127-32. 2004..This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC... - Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerCharles M Rudin
University of Chicago, Illinois, USA
J Clin Oncol 22:1110-7. 2004..A dose-finding study was performed evaluating the combination of G3139, carboplatin, and etoposide in patients with previously untreated extensive stage SCLC... - Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumRobert Dreicer
Department of Hematology Oncology and Urologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Cancer 100:1639-45. 2004..The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) were compared in patients with advanced urothelial carcinoma... - Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancerJoshua R Sonett
Division of Cardiothoracic Surgery, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York 10032, USA
Ann Thorac Surg 78:1200-5; discussion 1206. 2004..Operative results and midterm survival follow-up are presented... - Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trialPrimo N Lara
University of California Davis Cancer Center, Sacramento, CA 95817, USA
Clin Lung Cancer 6:102-7. 2004..06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC... - Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101Antonius A Miller
Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
J Clin Oncol 25:3055-60. 2007..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction... - Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?Martin J Edelman
Expert Rev Anticancer Ther 3:127-9. 2003 - Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group studyQuynh Thu Le
Department of Radiation Oncology, Stanford University, Stanford, California 94305 5847, USA
Clin Cancer Res 10:5418-24. 2004..To determine the feasibility and a recommended phase II dose of tirapazamine when combined with chemoradiotherapy in limited-stage small cell lung cancer (LSCLC)... - Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancerPaul Ritch
Milwaukee Medical College, Milwaukee, USA
Lung Cancer 52:173-80. 2006..The addition of aprinocarsen to gemcitabine+carboplatin therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients... - Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara
University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
J Clin Oncol 26:463-7. 2008....
Research Grants
- CANCER AND LEUKEMIA GROUP BMartin Edelman; Fiscal Year: 2002..The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. ..
- PHASE I TRIALS OF ANTICANCER AGENTSMartin Edelman; Fiscal Year: 2002....